Kinaction (masitinib) / AB Science 
Welcome,         Profile    Billing    Logout  
 66 Diseases   14 Trials   14 Trials   518 News 


123456»
  • ||||||||||  Iclusig (ponatinib) / Takeda, Otsuka
    Clinical-Pathological Correlations in Ponatinib Reactions: Beyond the Typical Stevens-Johnson Syndrome Presentation. (Poster Area) -  Aug 5, 2024 - Abstract #EADV2024EADV_1914;    
    It is imperative for both healthcare professionals and patients to recognize these potential risks and diligently monitor for any signs of adverse reactions when starting new medications. Early detection and prompt intervention are essential to mitigate the risk of severe complications and to ensure the safe and efficacious utilization of novel therapies.
  • ||||||||||  Bosulif (bosutinib) / Pfizer, Kinaction (masitinib) / AB Science, saracatinib (AZD0530) / AstraZeneca
    Identification of Chemical Tool Compounds to Investigate the Role of Lyn Kinase in TREM2-Mediated Microglia Activation and Phagocytosis (Exhibit (Pennsylvania Convention Center); In-Person) -  Jun 19, 2024 - Abstract #AAIC2024AAIC_3687;    
    On the other hand, Type II inhibitors, such as Masitinib and Imatinib, displayed pronounced >20-fold selectivity for Lyn over Hck with low nM Lyn inhibitor activities... We have successfully evaluated previously reported inhibitors and introduced a novel type II Lyn kinase inhibitor with picomolar (pM) activities suitable for use as chemical probes to investigate the role of Lyn in TREM2-mediated microglial activation.
  • ||||||||||  Leqembi (lecanemab-irmb) / Biogen, BioArctic, Eisai
    P3 data, Journal:  Beyond lecanemab: Examining Phase III potential in Alzheimer's therapeutics. (Pubmed Central) -  Jun 13, 2024   
    However, Gantenerumab and Solanezumab, unsuccessful in Phase III, are not covered. While the future approval status remains uncertain, we hope these drugs will offer beneficial therapeutic effects for potential dementia patients.
  • ||||||||||  Kinaction (masitinib) / AB Science
    Preclinical, Review, Journal:  Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence. (Pubmed Central) -  Dec 18, 2023   
    However, further research is necessary to validate and expand upon these findings, particularly regarding the precise mechanisms through which masitinib exerts its therapeutic effects. Future studies should also focus on addressing the safety concerns associated with masitinib use.
  • ||||||||||  Kinaction (masitinib) / AB Science
    Review, Journal:  Advances in Understanding and Treating Amyotrophic Lateral Sclerosis (ALS): A Comprehensive Review. (Pubmed Central) -  Dec 13, 2023   
    Two medications, riluzole and edaravone, have recently been licensed for use in therapy, and they very slightly increase life expectancy...In the following article, we give a synopsis of the innovative medications and genetic remodeling that have emerged recently and help to halt the course of the illness. Studies have also been conducted on a few symptomatic and rehabilitative therapies that enhance the quality of life for ALS patients.
  • ||||||||||  Kinaction (masitinib) / AB Science
    Review, Journal:  Therapies from Thiopeptides. (Pubmed Central) -  Nov 29, 2023   
    The studies that produced such therapeutic resources are detailed in the second part. True to the theme of this issue, "Organic Synthesis and Medicinal Chemistry: Two Inseparable Partners", an important message is that the above advances would have never materialized without the support of curiosity-driven, academic synthetic organic chemistry: a beleaguered science that nonetheless has been-and continues to be-instrumental to progress in the biomedical field.
  • ||||||||||  Kinaction (masitinib) / AB Science
    Review, Journal:  A Scoping Review on Tyrosine Kinase Inhibitors in Cats: Current Evidence and Future Directions. (Pubmed Central) -  Oct 14, 2023   
    While toceranib phosphate and masitinib mesylate are licensed for use in dogs, no TKI is yet approved for cats...Exploring the clinical use of TKIs in mammary carcinomas holds promise. Despite the progress, currently, the evidence falls short, underscoring the need for further research to discover new indications in feline oncology and to bridge the knowledge gaps between human and feline medicine.
  • ||||||||||  Kinaction (masitinib) / AB Science
    Trial completion date, Trial primary completion date:  Masitinib in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) -  Oct 10, 2023   
    P3,  N=600, Not yet recruiting, 
    Despite the progress, currently, the evidence falls short, underscoring the need for further research to discover new indications in feline oncology and to bridge the knowledge gaps between human and feline medicine. Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Dec 2026
  • ||||||||||  Kinaction (masitinib) / AB Science
    Journal:  Masitinib Inhibits Hepatitis A Virus Replication. (Pubmed Central) -  Jun 14, 2023   
    Masitinib also significantly inhibited HAV HM175 internal ribosomal entry-site (IRES) activity. In conclusion, HuhT7-HAV/Luc cells are adequate for anti-HAV drug screening, and masitinib may be useful for the treatment of severe HAV infection.
  • ||||||||||  Kinaction (masitinib) / AB Science
    Clinical protocol, Journal:  Acupuncture for chronic low back pain in older adults: Design and protocol for the BackInAction pragmatic clinical trial. (Pubmed Central) -  May 8, 2023   
    P=N/A
    The BackInAction study offers an opportunity to further understand the effectiveness, dose-dependence, and safety of acupuncture in a Medicare population. Additionally, study results may encourage broader adoption of more effective, safer, and more satisfactory options to the continuing over-reliance on opioid- and invasive medical treatments for cLBP among older adults.
  • ||||||||||  Kinaction (masitinib) / AB Science
    Trial completion date, Trial primary completion date:  Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment (clinicaltrials.gov) -  May 6, 2023   
    P3,  N=140, Recruiting, 
    Additionally, study results may encourage broader adoption of more effective, safer, and more satisfactory options to the continuing over-reliance on opioid- and invasive medical treatments for cLBP among older adults. Trial completion date: Dec 2022 --> Jun 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
  • ||||||||||  Kinaction (masitinib) / AB Science
    Trial completion date, Trial primary completion date:  Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 (clinicaltrials.gov) -  Feb 6, 2023   
    P2,  N=78, Recruiting, 
    In addition, Masitinib CTs and other competitor drugs in phase 3 CTs have been discussed. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Kinaction (masitinib) / AB Science
    Enrollment open:  Masitinib in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) -  Feb 6, 2023   
    P3,  N=600, Recruiting, 
    Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Not yet recruiting --> Recruiting
  • ||||||||||  Kinaction (masitinib) / AB Science
    Journal:  Interaction of Masitinib with Organic Cation Transporters. (Pubmed Central) -  Nov 27, 2022   
    Clinical trials in humans and other animals with Masitinib have already shown promising results. However, further research is necessary to understand the disease specific transport mechanisms of Masitinib to contribute to a successful and responsible therapy employment.
  • ||||||||||  Kinaction (masitinib) / AB Science
    Journal:  C-kit inhibitor masitinib induces reactive oxygen species-dependent apoptosis in c-kit-negative HepG2 cells. (Pubmed Central) -  Sep 10, 2022   
    Thus, we demonstrated that the anticancer effects of masitinib are not due to its targeting c-kit, but rather to its targeting the redox balance via the JNK pathway in HepG2 cells. These results suggest that masitinib has the potential to provide a robust antitumor effect in tumor lesions and could also be applied to a broad range of other anticancer therapies.
  • ||||||||||  Journal:  Therapeutic news in Alzheimer’s disease: soon a disease-modifying therapy? (Pubmed Central) -  Aug 13, 2022   
    Treatments targeting the tau protein are less advanced but weak signals are emerging from immunotherapies in the moderate stages of the disease (semorinemab). There is renewed hope for patients since it may not be unreasonable that these disease-modifying therapies will be part of the French therapeutic arsenal within the next five years.